Abstract: The present disclosure provide for methods of using 6-thio-2?-deoxyguanosine (6-thio-dG) to treat telomerase-positive cancers that exhibit (a) one or more TERT promoter mutations, and/or (b) enriched telomere transcriptional signature(s). In particular, melanomas, including those who are not sensitive or have become resistant to immune checkpoint inhibition and/or MAPKi therapy are targets for this therapy.

Abstract: The present disclosure describes purified telomerase holoenzyme and its delivery to cells, such as T cells, for increasing telomere length, increasing cell proliferation, and impeding cell senescence.

Abstract: The present disclosure encompasses methods and compositions for analyzing telomeres of genomic DNA, including the length of one or more telomeres. In specific embodiments, methods and compositions are employed for identification of the length of the shortest telomere in a collection of genomic DNA. In particular cases, the method greatly suppresses amplification of intra-genomic DNA fragments in comparison to telomeres by hindering their amplification using particular adaptors.

Abstract: The described invention provides small molecule anti-cancer compounds that selectively target and inhibit measurable biological activity of truncated APC proteins, an immortalized Human Colonic Epithelial Cell (HCEC) model, and pharmaceutical compositions comprising at least one of the small molecule anti-cancer compounds and a pharmaceutically acceptable carrier.

Abstract: Methods for treating a telomerase-expressing cell characterized by an over-activation of telomerase in a subject in need thereof comprising administering a pharmaceutical composition comprising a first amount of a 6-mercaptopurine analog, and a second amount of a telomerase inhibitor, wherein the first amount and the second amount together comprises an amount effective to reduce stability of telomere length and to induce cell death in the telomerase-expressing cell are provided. The methods can be used to treat patients with lung cancer, colon cancer, or cervical cancer.

Abstract: The present disclosure provide for methods of using 6-thio-2?-deoxyguanosine (6-thio-dG) to treat telomerase-positive cancers that exhibit (a) one or more TERT promoter mutations, and/or (b) enriched telomere transcriptional signature(s). In particular, melanomas, including those who are not sensitive or have become resistant to immune checkpoint inhibition and/or MAPKi therapy are targets for this therapy.

Abstract: The described invention provides small molecule anti-cancer compounds that selectively target and inhibit measurable biological activity of truncated APC proteins, an immortalized Human Colonic Epithelial Cell (HCEC) model, and pharmaceutical compositions comprising at least one of the small molecule anti-cancer compounds and a pharmaceutically acceptable carrier.

Abstract: The present disclosure encompasses methods and compositions for analyzing telomeres of genomic DNA, including the length of one or more telomeres. In specific embodiments, methods and compositions are employed for identification of the length of the shortest telomere in a collection of genomic DNA. In particular cases, the method greatly suppresses amplification of intra-genomic DNA fragments in comparison to telomeres by hindering their amplification using particular adaptors.

Abstract: The described invention provides methods for targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis.

Abstract: The described invention provides small molecule anti-cancer compounds that selectively target and inhibit measurable biological activity of truncated APC proteins, an immortalized Human Colonic Epithelial Cell (HCEC) model, and pharmaceutical compositions comprising at least one of the small molecule anti-cancer compounds and a pharmaceutically acceptable carrier.

Abstract: Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3??P5? thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells.

Abstract: The described invention provides methods for targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis.

Abstract: The described invention provides small molecule anti-cancer compounds that selectively target and inhibit measurable biological activity of truncated APC proteins, an immortalized Human Colonic Epithelial Cell (HCEC) model, and pharmaceutical compositions comprising at least one of the small molecule anti-cancer compounds and a pharmaceutically acceptable carrier.

Abstract: Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3??P5? thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells.

Abstract: The present disclosure is directed toward pharmaceutical compositions and methods of using 6-mercaptopurine ribosides and analogs thereof for the treatment of cancer and other hyperproliferative diseases. The described compounds can be converted into telomere substrates in vivo and can be recognized by telomerase for incorporation into telomeres of telomerase active cells, leading to induction of cell death of the telomerase active cells.

Abstract: Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3??P5? thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells.

Abstract: Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3?->P5? thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells.

Abstract: Methods and kits are provided for diagnosis of specific cancerous conditions. The invention features a method for diagnosis of a condition in a patient associated with an elevated level of telomerase activity within a cell. The method involves determining the presence or amount of telomerase within the cells in the patient, e.g. by the use of the polymerase chain reaction. In one embodiment of the invention, the condition associated with elevated telomerase activity is chosen from prostate cancer, breast cancer, colon cancer, renal cancer, ovarian/cervical cancer, lung cancer, and leukemia. The invention allows cancer to be detected even in tissues and cells which are not positive by pathology.

Abstract: The invention relates to peptide nucleic acids that inhibit telomerase activity in mammalian cells.

Abstract: A method of extracting telomerase from a cell sample having telomerase is provided which includes the step of contacting a cell sample with a buffer having (i) a non-ionic detergent at a concentration of not more than 5% (v/v) and (ii) an ionic detergent at a concentration of not more than 1 mM, to form a cell lysate. The method provides efficient extraction of telomerase that can be assayed for diagnostic and prognostic purposes.